Search Results

You are looking at 1 - 6 of 6 items for :

  • "abiraterone" x
Clear All
Authors: Zsófia Küronya, Krisztina Bíró, Lajos Géczi and Anikó Maráz

folyamatok kasztrációrezisztens prosztatadaganatban.] Orv Hetil. 2017; 158: 42–49. 15 de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic

Restricted access
Authors: Tibor Szarvas, Anita Csizmarik, Nikolett Nagy, Dávid Keresztes, Melinda Váradi, Zsófia Küronya, Péter Riesz and Péter Nyirády

. 2019; 18: e482. 18 de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011

Open access
Authors: Nikoletta Szabó, Jovana Ajduković, Evgenija Djurendić, Marija Sakač, Imre Ignáth, János Gardi, Gábor Mahmoud, Olivera Klisurić, Suzana Jovanović-Šanta, Katarina Penov Gaši and Mihály Szécsi

, G., de Bono, J. S. (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26, 4563

Restricted access
Authors: Zsófia Küronya, Krisztina Bíró, Fruzsina Gyergyay and Lajos Géczi

., 1993, 11 (11), 2167–2172. 15 Yin, L., Hu, Q.: CYP17 inhibitors – abiraterone, C17,20-lyase inhibitors and multi-targeting agents. Nat. Rev. Urol., 2014, 11

Restricted access
Authors: Tibor Szarvas, Anita Csizmarik, Miklós Szűcs and Péter Nyirády

metasztatikus kasztrációrezisztens prosztatadaganatban.] Orv Hetil. 2017; 158: 42–49. [Hungarian] 13 de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in

Open access

. 2 Attard , G , Reid , AH , A’Hern , R et al. 2009 Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742 – 3748

Restricted access